Grass pollen-derived immunotherapy

Unassigned

New Medicines

Moderate to severe grass pollen-induced seasonal allergic rhinoconjunctivitis in adults aged 18–64 years

Information

New molecular entity
ASIT Biotech
ASIT Biotech

Development and Regulatory status

None
Phase III Clinical Trials
None

Category

A peptide hydrolysate from Lolium perenne, consisting of highly purified natural allergen fragments. The ASIT+ allergen fragments rapidly triggers a protective immune response without need of an adjuvant. Given as 4 doses over 3 weeks.
Allergic rhinitis is a common problem, affecting over 20% of the UK population. Grass pollens usually cause symptoms from late spring to early summer. Main lines of treatment are education, allergy avoidance, antihistamines and topical steroids [1]. NHS England has estimated that ~20,000 people in England require referral to a specialist centre for severe allergy, with half of those receiving specialist interventions such as immunotherapy or investigation for drug allergy [2].
Moderate to severe grass pollen-induced seasonal allergic rhinoconjunctivitis in adults aged 18–64 years
Subcutaneous injection